

Article title: Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature

Journal name: International Journal of Health Policy and Management (IJHPM)

Authors' information: Chanthawat Patikorn¹, Suthira Taychakhoonavudh¹, Rungpetch Sakulbumrungsil¹, Dennis Ross-Degnan², Puree Anantachoti^{1*}

¹Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

²Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care

Institute, Landmark Center, Boston, MA, USA.

(*Corresponding author: puree.a@chula.ac.th)

Supplementary file 3. Strategies to Facilitate Access to High-Cost Anticancer Drugs by Country

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
High-income countries												
Antigua and Barbuda	/											
Australia		/	/	/	/	/	/				/	

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Austria		/		/								
Bahamas										/		
Bahrain	/											
Barbados	/									/		
Belgium		/	/	/	/							
Canada		/		/	/					/		
Chile	/	/			/					/		
Croatia	/	/	/	/		/			/			
Czech Republic	/	/	/	/								
Denmark		/	/		/							
Estonia	/	/	/	/								
Finland		/	/	/								
France		/	/	/	/	/			/			
Germany		/	/	/		/						
Greece		/			/							

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Hong Kong		/			/						/	
Hungary		/	/	/		/						
Iceland		/	/									
Ireland		/	/									
Israel		/	/	/								
Italy		/	/	/	/		/					
South Korea	/	/	/	/		/	/			/		
Latvia	/	/	/	/	/	/						
Lithuania	/	/	/	/		/						
Luxembourg		/		/								
Malta	/	/		/								
Mauritius										/		
Monaco		/										
Nauru	/											
Netherlands		/	/	/	/	/	/		/			

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
New Zealand		/		/						/		
Norway		/	/	/								
Oman	/											
Palau	/											
Panama										/		
Poland	/	/	/	/	/	/						
Portugal	/	/	/	/								
Romania	/	/	/	/		/						
Seychelles	/									/		
Singapore		/				/				/		
Slovakia	/	/	/		/	/	/					
Slovenia	/	/	/	/								
Spain		/	/	/								
St. Kitts and Nevis	/											
Sweden	/	/	/	/	/		/					

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Switzerland		/		/								
Taiwan		/		/	/	/						
Trinidad and Tobago	/											
United Kingdom		/		/	/	/	/					
United States				/	/	/		/	/	/	/	/
Uruguay	/	/			/					/		
Upper middle-income countries												
Albania			/								/	
Argentina	/	/									/	
Armenia	/										/	
Azerbaijan											/	
Belarus	/	/									/	
Belize	/											
Bosnia and Herzegovina	/	/		/	/							
Botswana	/										/	

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Brazil	/	/		/								
Bulgaria	/	/	/	/								
China	/	/		/				/	/	/		
Colombia	/	/								/		
Costa Rica	/									/		
Cuba	/											
Dominica	/											
Dominican Republic	/									/		
Ecuador	/	/								/		
Fiji	/									/		
Gabon	/									/		
Georgia	/									/		
Grenada	/											
Guatemala										/		
Guyana	/											

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Indonesia	/	/								/		
Iran	/	/							/			
Iraq	/											
Jamaica	/				/					/		
Jordan	/	/										
Kazakhstan		/			/	/				/		
Lebanon	/											
Macedonia	/	/										
Malaysia	/	/								/		
Maldives	/											
Marshall Islands	/											
Mexico	/	/	/		/			/		/		
Montenegro	/											
Namibia	/									/		
Paraguay	/									/		

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Peru	/									/		
Russia	/	/	/		/	/		/		/		
Serbia	/	/		/								
South Africa	/	/								/		
St. Lucia	/									/		
St. Vincent and the Grenadines	/											
Suriname	/									/		
Thailand	/	/		/	/		/			/		
Tonga	/											
Turkey		/	/	/		/				/		
Tuvalu	/											
Venezuela	/				/					/		
Lower middle-income countries												
Algeria	/											
Angola	/											

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Bangladesh	/									/		
Benin										/		
Bhutan	/									/		
Bolivia	/									/		
Cabo Verde	/									/		
Cambodia	/									/		
Cameroon	/									/		
Congo, Republic	/									/		
Côte d'Ivoire	/									/		
Djibouti	/											
Egypt	/											
El Salvador	/									/		
Ghana	/									/	/	
Honduras	/									/		
India	/	/						/	/	/		

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Kenya	/									/		
Kyrgyzstan	/		/							/		
Kiribati	/											
Laos										/		
Lesotho	/									/		
Liberia	/											
Mauritania	/									/		
Moldova	/									/		
Mongolia	/									/		
Morocco	/									/		
Myanmar	/											
Nepal	/									/		
Nicaragua	/									/		
Nigeria	/									/		
Pakistan	/									/		

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Papua New Guinea	/									/		
Philippines	/									/		
Senegal	/									/		
Solomon Islands	/									/		
Sri Lanka	/									/		
Swaziland										/		
Tanzania	/									/		
Timor-Leste	/									/		
Tunisia	/											
Ukraine	/	/	/									
Uzbekistan		/								/		
Vanuatu	/											
Vietnam	/	/								/		
Zambia	/									/		
Zimbabwe	/									/		

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Low-income countries												
Afghanistan	/											
Burkina Faso	/									/		
Burundi	/											
Central African Republic	/									/		
Chad	/											
Congo, Democratic Republic	/									/		
Eritrea	/											
Ethiopia	/									/		
Gambia	/											
Guinea	/									/		
Haiti	/									/		
North Korea	/											
Madagascar	/									/		
Malawi	/									/		

Country	Standard pharmaceutical reimbursement and pricing policies			Funding strategies specific to high-cost drugs					Financial assistance for individual patients			
	WHO List of essential medicines	National Health Technology Assessment	Reference pricing systems	Managed entry agreement	Dedicated funds for high-cost drugs	Orphan drug reimbursement	Adjusted cost-effectiveness threshold	Use of compulsory licensing	Health insurance scheme for the poor	Patient cost-sharing reduction/exemption	Patient Assistance Program	Assistance Foundations
Mali	/									/		
Mozambique	/									/		
Niger										/		
Rwanda	/									/		
Sierra Leone										/		
Somalia	/											
Sudan	/									/		
Syrian Arab Republic	/											
Tajikistan	/									/		
Togo	/									/		
Uganda	/									/		
Yemen	/											